In short
Clinical trials in this article study Liraglutide in different groups, including adults with obesity, children with obesity, healthy volunteers, and people with type 2 diabetes. These studies look at how well it works, how safe it is in research settings, and what changes it may cause in weight, hunger, or other health measures.
Key points
- Clinical trials of Liraglutide in the provided data focus mostly on obesity, including studies in adults and children. One Phase 3 study also looks at healthy volunteers to measure stomach movement, hunger, and food intake. Another Phase 3 study in children with obesity measures BMI change over time. The data also include a large Phase 3 diabetes study where Liraglutide is one of several treatments being compared in a broader treatment plan. Across these trials, the main outcomes are weight-related measures, digestive activity, hunger, and blood sugar control.
Overview of the clinical trials
The provided trial data show research on Liraglutide in several groups, mainly people with obesity and children with obesity, plus healthy volunteers and people with type 2 diabetes. The studies are in Phase 2 and Phase 3, which means they are testing effects in research settings and comparing outcomes in larger groups. The main goals are to measure changes in body weight, BMI, hunger, stomach activity, and blood sugar control.
Trials in adults with obesity
One Phase 2 study, NCT2024-513679-42-00, enrolled 255 adults with obesity or overweight and was completed. It compared multiple dose levels of PF-07976016 against placebo in participants with obesity on a background of liraglutide, and it also included Saxenda as a study treatment listed in the data. The main outcome was the percent change in body weight at Week 16.
This study is important because it focuses on whether adding another study medicine can change weight more than placebo in people already receiving liraglutide-based background treatment. The trial was interventional, which means researchers gave the study treatments and then measured the effects.
Trials in children with obesity
One Phase 3 study, NCT2023-508504-38-00, is authorised and includes 82 children aged 6 to under 12 years with obesity. The study compares Liraglutide 3.0 mg once daily with placebo for weight management in this age group. The main outcome is the relative change in BMI from Week 0 to Week 56.
This trial is focused on a younger population, so it helps answer whether the study treatment can support weight-related care in children with obesity. The use of BMI change as the main outcome shows that the trial is measuring growth-related weight patterns over time, not just short-term change.
Trials in healthy volunteers
Another Phase 3 study, NCT2024-518641-21-00, is authorised and includes 15 healthy volunteers. It studies the effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings, and ad libitum food intake. The main outcome is to detect changes in MMC activity after administration of liraglutide compared with placebo.
This type of study does not focus on a disease group alone; instead, it helps researchers observe how the study treatment affects digestive patterns and hunger in people without the target condition. The trial uses saline as the placebo comparison and measures several body responses at once.
Trial in type 2 diabetes
The provided data also include a large Phase 3 study, NCT05433584, in 781 adult participants with type 2 diabetes. In this trial, Liraglutide appears among several treatment options in a study comparing tirzepatide with intensified conventional care. The main outcome is the change from baseline in HbA1c.
This study is not only about one medicine, but it still shows that liraglutide is part of the treatment list being studied in people with type 2 diabetes. HbA1c is a key diabetes measure because it reflects average blood sugar over time.
Main outcomes and what they mean
Across these trials, the main outcomes are practical measures that matter to patients and researchers. The obesity studies look at body weight and BMI, which are common ways to track weight change. The healthy volunteer study looks at stomach movement, hunger, and food intake, which helps show how the body responds after treatment. The diabetes study uses HbA1c, which helps show longer-term blood sugar control.
The trial data also show different study sizes, from 15 healthy volunteers to 781 people in the diabetes study. This range suggests that the research questions are different: some studies are small and focused on body responses, while others are larger and compare treatment effects in broader patient groups.